Botulin Toxin Use in Scars/Keloids Treatment

  • Jacopo Scala University Guglielmo Marconi, Rome, Italy
  • Aleksandra Vojvodic Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia
  • Petar Vojvodic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Tatjana Vlaskovic-Jovicevic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Zorica Peric-Hajzler Military Medical Academy, Belgrade, Serbia
  • Dusica Matovic Military Medical Academy, Belgrade, Serbia
  • Sanja Dimitrijevic Department of Gynecology, Military Medical Academy, Belgrade, Serbia
  • Jovana Vojvodic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Goran Sijan Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia
  • Nenad Stepic Chief of Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia
  • Uwe Wollina Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany
  • Michael Tirant G. Marconi University, Rome, Italy
  • Van Thuong Nguyen Vietnam National Hospital of Dermatology and Venereology, Hanoi, Vietnam
  • Massimo Fioranelli Department of Nuclear Physics, sub-nuclear and radiation, G. Marconi University, Rome, Italy
  • Torello Lotti University of Rome G. Marconi, Rome, Italia
Keywords: botulin toxin, scars, keloids


Botulinum toxin (BTX) is a neurotoxin protein derived from the Clostridium botulinum bacterium that inhibits the release of acetylcholine at the neuromuscular junction level whose effects has been used for many years to treat a variety of muscular/neuromuscular conditions and more recently also for cosmetic use.

BTX has experimented in some dermatological conditions which include scar prevention and treatment with good results. The complex mechanism underlying those results is not completely understood but several mechanisms were proposed: release inhibition of different substances like (TGF)-β, substance P, calcitonin gene-related peptide (CGRP) and glutamate thus modulating cutaneous inflammation and wound healing.

We analysed the published data on BTX off label applications on scars and keloids retrieved from PubMed.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block

Author Biography

Torello Lotti, University of Rome G. Marconi, Rome, Italia

Prof. Lotti is Full Professor of the Dermatology and Venereology at University of Studies Guglielmo Marconi, Rome, Italy. He is Honorary Professor of Dermatology - China Medical University Shenyang (2011), Lecturer at the New York Academy of Sciences "Howard Fox Memorial Lecture" (14 March 2012 - New York, NY – USA), and Chair, Executive Scientific Committee Vitiligo Research Foundation, New York , NY , USA. He is President of the World Health Academy, Dermatology since 2013. He has been Full Professor of the Dermatology and Venereology Division at University of Florence School of Medicine, Florence, Italy, from 2006 to 2010. He is Visiting Professor in six International Universities worldwide, and Key Note Lecturer in several international dermatology Societies. His activities in serving Dermatology have been numerous: President of the Italian Society of Dermatology and Venereology (SIDeMaST , 2009-2010) and President of the International Society of Dermatology ( ISD, 2009-2010), President of the European Society for Cosmetic and Aesthetic Dermatology (2003-2004), Editor in Chief of the Journal of the European Academy of Dermatology and Venereology (1992-2002) , Editor "Therapeutic Hotline"- Dermatologic Therapy (2007-)and served as Editor in Chief of the Giornale Italiano di Dermatologia in the period of presidency of the Societa' Italiana di Dermatologia (2009-2010). He has been President of numerous international congresses and is currently Editor in Chief of the Giornale Italiano di Dermatologia e Venereologia ( 2010-2020 ). He is Ordinary Member of the main Scientific Societies worldwide (EADV, SIDEV , ESDR , ISD, AAD, SID) and Honorary Member of several Scientific Societies of the Dermatology field. Moreover, he is a Scientific reviewer of ten sectorial journals, among which are the British Journal of Dermatology, Journal of Investigative Dermatology, Journal of the American Academy of Dermatology , Dermatologic Therapy. He has authored 1054 scientific publications (393 peer reviewed articles, 288 books chapters e 365 abstracts). For more information, see


Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993; 365(6442):160-163. PMid:8103915

França K, Kumar A, Fioranelli M, Lotti T, Tirant M, RocciaMG. The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr. 2017; 167(1):46-48. PMid:28299552

França K, Castillo D, Lotti T. Non-cosmetic dermatological use of botulinum neurotoxin. Dermatol Ther. 2017; 30(4). PMid:28425626

Guida S, Farnetani F, Nisticò SP, Giorgio Mariarosaria C, Babino G, Giovanni Pellacani G, Fulgione E. New trends in botulinum toxin use in dermatology. Dermatol Pract Concept. 2018; 8(4):277-282. PMid:30479855 PMCid:PMC6246063

Schlessinger J, Gilbert E, Cohen JK, Kaufman J. New Uses of AbobotulinumtoxinA in Aesthetics. Aesthet Surg J. 2017; 37(1): S45-S58. PMid:28388720 PMCid:PMC5434494

Steinhoff M, Stander S, Seeliger S, Ansel JC, Schmeiz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch. Dermatol. 2003; 139:1479-1488.

Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N, Payan D. Skin-nervous system interactions. J. Investig. Dermatol. 1996; 106:198-204. PMid:8592075

Elhefnawy AM. Assessment of intralesional injection of botulinum toxin type A injection for hypertrophic scars. Indian J. Dermatol. Venereol. Leprol. 2016; 82:279-283. PMid:27088929

Shaarawy E. Hegazy RA, Abdel Hay RM. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: A randomized controlled trail. J. Cosmet. Dermatol. 2015; 14:161-166. PMid:25810045

Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: A preliminary report. Aesthet. Plast. Surg. 2009; 33:409-412. PMid:19357910

Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast. Reconstr. Surg. 2009; 124:275e-277e. PMid:20009818

Jablonka EM, Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2012; 28(5):525-535. PMid:23027220

Gauglitz GG. Management of keloids and hypertrophic scars: current and emerging options. Clin Cosmet Investig Dermatol. 2013; 6:103-114. PMid:23637546 PMCid:PMC3639020

Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T, Schauber J. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol. 2012; 25(6):313-318. PMid:22948093

Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS. Early postoperative treatment of thyroidectomy scars using botulinum toxin: A split-scar, double-blind, randomized controlled trial. Wound Repair Regen. 2014; 22:605-612. PMid:24898579

Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P, Yachouh J. Use of botulinum toxin type A to improve treatment of facial wounds: A prospective randomized study. J. Plast. Reconstr. Aesthet. Surg. 2013; 66:209-214. PMid:23102873

Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, Sherris DA. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin. Proc. 2006; 81:1023-1028. PMid:16901024

Galárraga IM. Use of botulinum toxin in cheiloplasty: A new method to decrease tension. Can J Plast Surg. 2009; 17(3):e1-e2. PMid:20808741 PMCid:PMC2740606

Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair. Plast Reconstr Surg. 2014; 134(3):511-516. PMid:25158709

Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast. Reconstr. Surg. 2006; 117:1758-1766. PMid:16651948

Chen M, Yan T, Ma K, et al. Botulinum toxin type A inhibits α smooth muscle actin and myosin II expression in fibroblasts derived from scar contracture. Ann Plast Surg. 2016; 77(3):e46-e49. PMid:25144422

Xiao Z, Qu G. Effects of botulinum toxin type a on collagen deposition in hypertrophic scars. Molecules. 2012; 17(2):2169-2177. PMid:22354193 PMCid:PMC6268678

Jeong HS, Lee BH, Sung HM, et al. Effect of botulinum toxin type A on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg. 2015; 136(2):171e-178e. PMid:26218391

Zhang DZ, Liu XY, Xiao WL, Xu YX. Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials. PLoS One. 2016; 11(3):e0151627. PMid:26985661 PMCid:PMC4795777

Xiao Z, Zhang M, Liu Y, Ren L. Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthetic Plast Surg. 2011; 35(5):802-807. PMid:21455826

Xiao Z, Zhang F, Lin W, Zhang M, Liu Y. Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesthetic Plast Surg. 2010; 34(4):424-427. PMid:19802513

Huang C, Akaishi S, Hyakusoku H, Ogawa R. Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. Int Wound J. 2014; 11(5):517-522. PMid:23173565

Haubner F, Leyh M, Ohmann E, Sadick H, Gassner HG. Effects of botulinum toxin A on patient-specific keloid fibroblasts in vitro. Laryngoscope. 2014; 124(6):1344-1351. PMid:24122729

Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008; 88(6):579-590. PMid:18427552 PMCid:PMC2810253

Viera, M.H.; Amini, S.; Valins, W.; Berman, B. Innovative therapies in the treatment of keloids and hypertrophic scars. J. Clin. Aesthet. Dermatol. 2010; 3:20-26.

Uyesugi B, Lippincott B, Dave S. Treatment of painful keloid with botulinum toxin type A. Am. J. Phys. Med. Rehabil. 2010; 89:153-155. PMid:19884811

Kellogg Jr DL, PeÌrgola PE, Piest KL, Kosiba WA, Crandall CG, Grossmann M, Johnson JM. Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ. Res. 1995; 77:1222-1228. PMid:7586235

Carmichael MM, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain. 2010; 149:316-324. PMid:20223589

How to Cite
Scala J, Vojvodic A, Vojvodic P, Vlaskovic-Jovicevic T, Peric-Hajzler Z, Matovic D, Dimitrijevic S, Vojvodic J, Sijan G, Stepic N, Wollina U, Tirant M, Nguyen VT, Fioranelli M, Lotti T. Botulin Toxin Use in Scars/Keloids Treatment. Open Access Maced J Med Sci [Internet]. 2019Aug.30 [cited 2020Oct.26];7(18):2979-81. Available from:

Most read articles by the same author(s)

1 2 3 > >>